[1] SURIAWINATA A,XU R. An update on the molecular geneties of hepatocellular carcinoma[J]. Semin Liver Dis,2004,24：77-78.
[2] 刘妲妲,王全楚. 输血后丙型肝炎患者的临床特点及自然病程[J]. 实用肝脏病杂志,2008,11（6）：410-411.
[3] OLIZZOTTO MN,WOOD EM,INGHAM H,et al. Reducing the risk of transfusion-transmissible viral infection through blood donor selection：the Australian experience 2000 through 2006[J]. Transfusion,2008,48（1）：55-63.
[4] QIU Y,SHI L,WANG Y,et al. Risk factors for hepatitis C virus infection among blood donors in Beijing and implications for improving the pretesting donor screening pocess[J]. Transfusion,2008,48（6）：1207-1212.
[5] THONGSAWAT S,MANEEKARN N,KUNIHOLM MH,et al. Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand[J]. J Med Virol,2008,80（5）：808-815.
[6] TAYLOR A,HUTCHINSON SJ,GILCHRIST G,et al. Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in glasgow[J]. Harm Reduct J,2008,5（1）：11.
[7] PALMATEER N,ANDERSON N,WADD S,et al. Exploring associations between perceived HCV status and injecting risk behaviors among recent initiates to injecting drug use in glasgow[J]. Subst Use Misuse,2008,43（3）：375-388.
[8] 中华医学会肝病学会和传染病与寄生虫病学分会. 丙型肝炎防治指南[J]. 实用肝脏病杂志,2004,7：1-6.
[9] SEEFF LB. Natural history of chronic hepatitis C[J]. Hepatology,2002,36：S35-46.
[10] FATTOVICH G,GIUSTINA G,DEGOS F,et al. Morbidity and mortality in compensated cirrhosis type C： a retrospective follow-up study of 384 patients[J]. Gastroenterology,1997,112：463-472.
[11] JOHN-BAPTISTE AA,TOMLINSON G,HSU PC,et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for Hepatitis C[J]. Am J Gastroenterol,2009,04（10）：2439-48.
[12] KANG SM,CHOI SH, PARK CY,et al. Monoclonal antibody recognizing N2terminal epitope of hepatitis C virus non-structural 5B inhibit s viral RNA replication[J]. J Viral Hepat,2008,15（4）：305-313.
[13] MORATORIO G,MARTINEZ M,GUTIERREZ MF,et al. Evolution of naturally occurring 5′non-coding region variant s of Hepatitis C virus in human populations of the South American region[J]. Virol J,2007,4（1）：7-9.
[14] 高玉红,李峥,台虹. 丙型肝炎病毒基因分型方法研究进展[J]. 国际检验医学杂志,2006,27（10）：908-910.
[15] 于建武,赵勇华,李树臣. 丙型肝炎病毒血清型对慢性丙型肝炎患者早期病毒学应答和生化应答的影响[J]. 肝脏,2007,12（1）：8.
[16] KOHASHI T,MAEKAWA S,SAKAMOTO N,et al. Site -specific mutation of the interferon sensitivity-determining region（ISDR） modulates hepatitis C virus replication[J]. J Viral Hepat,2006,13（9）：582-590.
[17] UKAI K,ISHIGAMI M,YOSHIOKA K,et al. Mutations in carboxy-terminal part of Eincluding PKR/eIF2α-phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b：Their correlation with response to interferon monotherapy and viral load[J]. World J Gastroenterol,2006,12（23）： 3722-3728.
[18] TAN SL,PAUSE A,SHI Y,et al. Hepatitis C therapeutics：current status and emerging strategies[J]. Nat Rev Drug Discov,2002,1（11）：867-881.
[19] DE FRANCESCO R,RICE CM. New therap ies on the horizon for hepatitis C：are we close[J]. Clin LiverDis,2003,7（1）：211-242.
[20] 姚海云,房桂青,韩雪莹. 丙型肝炎患者血清HCV RNA定量与抗-HCV检测效果分析[J]. 中国输血杂志,2008,21（7）：535.
[21] ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER（APASL） HEPATITIS C WORKING PARTY,MCCAUGHAN GW,OMATA M,et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis,management and treatment of hepatitis C virus infection[J]. J Gastroenterol Hepatol,2007,22（5）：615-33.
[22] 郭振华,陈青锋,肖萍,等. HCV基因分型与干扰素疗效相关性探讨[J]. 临床检验杂志,2008,26（4）：306.
[23] GLUE P,FANG JW,ROZIER-PANIS R,et al. Pegylated interfon alfa-2b：Pharmacokinetics,pharmacodynamics,safety and Preliminary efficaly data[J]. Clin Pharmacol Ther,2000,68：556-567.
[24] MANNSMP,MCHVTCHISON JG,GORDON SC,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C：a randomized trial[J]. Lancet,2001,358：958-965.
[25] FELD JJ,HOOFNAGLE JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C[J]. Nature,2005,436：967-972.
[26] GHANY MG,STRADER DB,THOMAS DL,et al. AASLD PRACTICE GU IDEL INES：diagnosis,management,and treatment of hepatitis C：an update[J]. Hepatology,2009,49（4）：1335-1374.
[27] FRIED MW,SHIFFMAN ML,REDDY R,et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J]. N Engl J Med,2002,347：975-982.
[28] 徐道振,谢尧,陆志檬,等. 聚乙二醇干扰素a-2a与干扰素a-2a治疗慢性丙型肝炎疗效、安全性的评估[J]. 中华传染病杂志,2004,22：221-224.
[29] 马烈,赵辉,谢尧,等. 干扰素治疗慢性丙型肝炎的持续应答与复发相关因素的研究[J]. 中华肝脏病杂志,2006,4：565-568. |
